DIABETES trial. 149 patients with type 2 diabetes (1/3 on insulin) and native coronary lesions appropriate for stent implantation . Cypher sirolimus-eluting stent. Bare-metal stent. Primary Endpoint: In-stent and late lumen loss at 9 months (determined by QCA) Secondary Endpoints:
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
149 patients with type 2 diabetes (1/3 on insulin) and native coronary lesions appropriate for stent implantation
Cypher sirolimus-eluting stent
Presented at TCT 2004
Presented at ACC Scientific Sessions 2004
Angiographic restenosis, TLR, and overall MACE were significantly reduced. (Reduction in overall MACE was primarily due to the reduction in TLR – rates of cardiac death and MI were not significantly different between the two groups.)